breast cancer and glp 1 GLP-1 Receptor Agonists Show a Striking Signal in Outcomes, but Big Questions Remain GLP-1 use linked to lower

This appointment should include: Complete medication review : Disclose all prescription medications, over-the-counter drugs, and supplements Medical history assessment : Discuss previous mental health treatment, weight management attempts, and relevant conditions Baseline measurements : Blood pressure, weight, BMI, and potentially blood tests (renal function, liver function, HbA1c) Treatment goals : Establish realistic expectations for both depression management and weight loss Contraception discussion : If you're a woman of childbearing age, discuss effective contraception while taking semaglutide During treatment , contact your healthcare provider if you experience: Urgent concerns requiring same-day assessment : Suicidal thoughts or self-harm urges Severe, persistent vomiting or inability to keep fluids down Severe abdominal pain, especially if radiating to the back Signs of allergic reaction (rash, swelling, breathing difficulties) Rapid or irregular heartbeat with chest discomfort Non-urgent issues warranting routine review : Persistent nausea affecting daily activities or nutrition Significant mood changes or increased anxiety Troublesome side effects not improving after 23 weeks Lack of therapeutic response after adequate trial periods Weight loss exceeding recommended rates (approximately 0.51 kg per week) Regular monitoring schedule : For antidepressants, NICE guidance (NG222) recommends review within 24 weeks of initiation (within 1 week for people under 30 or at increased suicide risk), then as clinically indicated

B-vitamin foods (eggs, fish, fortified cereals) support energy metabolism at the cellular level

If prescribed, youll receive a low starting dose thats carefully adjusted over time to improve tolerance and designed to minimize side effects

A single amphetamine infusion reverses deficits in dopamine nerve-terminal function caused by a history of cocaine self-administration

Expanding the labeled indication to include OSA opened the door to payer-supported access to GLP-1 therapy for patients with obesity-associated OSA, with the potential to reduce reliance on devices